Statistics for Inhibikase Therapeutics (id:6056 IKT)

Valuation metrics

Market cap

134.84M

Enterprise value

10.03M

Trailing P/E (ttm)

-0.65

Forward P/E

-8.20

PEG ratio

-8.20

Price/Sales (ttm)

1.69K

Price/Book (mrq)

1.15

Enterprise Value/Revenue

126.06

Enterprise Value/EBITDA

-0.53

Overview

Shares outstanding

65.77M

Float

1.70M

Shares short

187.95K

% Held by insiders

0.10%

% Held by institutions

0.12%

Average volume (10 days)

397.93K

Average volume (90 days)

Price summary

52-Week low

0.85

52-Week high

3.82

52-Week change

62.34%

Beta

1.12

50-Day moving average

1.83

200-Day moving average

1.79

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

June 30th, 2023

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

June 30th, 2024

Profitability

Profit margin

0.00%

Operating margin

-23,885.05%

Operational effectiveness

Return on assets

-76.21%

Return on equity

-149.69%

Income statement

Revenue (ttm)

0.01

Revenue per share (ttm)

0.01

Quarterly revenue growth (yoy)

Gross profit (ttm)

0.00

EBITDA

-18,979,048.00

Net income to common (ttm)

-18,382,382.00

Diluted EPS (ttm)

-3.21

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

7.94M

Total cash per share (mrq)

1.06

Total debt (mrq)

355.09K

Total Debt/Equity (mrq)

6.97

Current ratio (mrq)

232.20%

Book value per share (mrq)

1.78

Cash flow

Cash flow statement

-16,468,916.00

Levered free cash flow (LFCF)

-10,339,925.00